Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Charity awards £1.5 million grant for glioma research
The researchers will trial the new treatment in Japan.

New treatment could be used to help both dogs and humans.

The Brain Tumour Charity has provided a “Quest for Cures” grant worth £1.5 million to support scientists working on a new immunotherapy drug for gliomas.

Led by Dr Jun Ishihara, from Imperial College London, the researchers are focusing on the protein interleukin 12 (IL-12), which is well-known for its anti-tumour effects and has long been studied as a possible cancer treatment.

Dr Ishihara’s team has added a collagen-binding site to IL-12. The researchers are also using novel nanotechnology to allow the treatment to cross the blood-brain barrier.

The UK researchers will work alongside vets at Nihon University in Japan to test the new treatment on dogs, offering it to owners as a possible treatment in cases where there are not usually other treatment options

The adapted IL-12 treatment will also be tested in the laboratory on glioblastoma cells, to help the researchers determine which types of cell are likely to respond best.

As gliomas in dogs are similar to those in humans, it is hoped the research could pave the way for human clinical trials in the future.

Professor Daisuke Ito, veterinary neurology specialist at Nihon University, said: “From the veterinary aspect, the study of gliomas in dogs and research into new treatments brings hope to dog owners.

“Current treatment in dogs is very similar to that in humans: surgery, radiotherapy and chemotherapy. This is very expensive for owners and requires access to specialist veterinary hospitals. Any new treatments that are less expensive and easier to access will be welcomed by dog owners across the globe.
“I consistently saw 2-5 canine glioma cases each month, so this disease is an issue for canine health too, and we need to find a cure. If we can find one that works for both people and dogs, that would be a real breakthrough!”


Image (C) Shutterstock

Become a member or log in to add this story to your CPD history

Special imports digital service set to change

News Story 1
 From Monday, 15 July, Special Import Certificate (SIC) applications will only be accepted via the Veterinary Medicines Directorate's (VMD's) new special imports digital service.

The original online special import scheme will be decommissioned. The VMD says that the new service is easier to use, more secure and reliable, and meets accessibility legislation.

The VMD is urging veterinary surgeons who have not yet signed up for the new service to do so before 15 July. The new digital service can be accessed here

Click here for more...
News Shorts
RCVS course explains concerns process

A free, online course from the RCVS Academy has been launched, designed to clarify RCVS' concerns procedure.

The content will give veterinary surgeons and veterinary nurses a better understanding of the process, and what they can expect if a concern is raised about them. It includes details of common concerns.

The interactive resource has been developed in collaboration with Clare Stringfellow, case manager in the RCVS Professional Conduct Team.

Ms Stringfellow said: "We appreciate that concerns can be very worrying, and we hope that, through this course, we can give vets and nurses a better understanding of the process and how to obtain additional support."

The course can be accessed via the RCVS Academy. Users are encouraged to record their learning for CPD.